Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS Trivalent Vaccine Second Dose in Healthy Non-pregnant Subjects
NCT02690181Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2016
- Primary completion
- Nov 2016
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of group b streptococcus trivalent vaccine in group B streptococcal infection (6 arms), sponsored by GSK. Primary endpoints: Percentage of Subjects With ELISA Antibody Concentrations of GBS Serotype Ia Above Pre-specified Thresholds at Day 61, Percentage of Subjects With Antibody Concentrations of GBS Serotype Ib Above Pre-specified Thresholds at Day 61 and 4 more. Started Mar 2016; status: completed.
02
Drugs
group b streptococcus trivalent vaccine
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT02690181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02690181.